Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.

[1]  Sandra Franco,et al.  Molecular Determinants of Multi-nucleoside Analogue Resistance in HIV-1 Reverse Transcriptases Containing a Dipeptide Insertion in the Fingers Subdomain , 2004, Journal of Biological Chemistry.

[2]  S. Swaminathan,et al.  Molecular Mechanisms of Tenofovir Resistance Conferred by Human Immunodeficiency Virus Type 1 Reverse Transcriptase Containing a Diserine Insertion after Residue 69 and Multiple Thymidine Analog-Associated Mutations , 2004, Antimicrobial Agents and Chemotherapy.

[3]  R. Shafer,et al.  Drug resistance mutations in HIV-1. , 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[4]  B. Clotet,et al.  Viral Evolution during Structured Treatment Interruptions in Chronically Human Immunodeficiency Virus-Infected Individuals , 2002, Journal of Virology.

[5]  E. Domingo,et al.  Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors. , 2002, Journal of molecular biology.

[6]  Bikram Chakraborty,et al.  Insertions in the Reverse Transcriptase Increase both Drug Resistance and Viral Fitness in a Human Immunodeficiency Virus Type 1 Isolate Harboring the Multi-Nucleoside Reverse Transcriptase Inhibitor Resistance 69 Insertion Complex Mutation , 2002, Journal of Virology.

[7]  B. Clotet,et al.  Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity , 2002, AIDS.

[8]  B. Larder,et al.  Phenotypic Susceptibilities to Tenofovir in a Large Panel of Clinically Derived Human Immunodeficiency Virus Type 1 Isolates , 2002, Antimicrobial Agents and Chemotherapy.

[9]  W. Heneine,et al.  Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Petropoulos,et al.  Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs , 2001, AIDS.

[11]  D. Stammers,et al.  Biochemical Mechanism of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistance to Stavudine , 2001, Antimicrobial Agents and Chemotherapy.

[12]  V. Calvez,et al.  Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus Type 1 Variants with Insertions or Deletions in the Reverse Transcriptase (RT): Multicenter Study of Patients Treated with RT Inhibitors , 2001, Antimicrobial Agents and Chemotherapy.

[13]  R. D. de Boer,et al.  Establishment of New Transmissible and Drug-Sensitive Human Immunodeficiency Virus Type 1 Wild Types due to Transmission of Nucleoside Analogue-Resistant Virus , 2001, Journal of Virology.

[14]  R. D. de Boer,et al.  Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs. , 2001, AIDS research and human retroviruses.

[15]  Miguel Ángel Martínez,et al.  Role of a dipeptide insertion between codons 69 and 70 of HIV‐1 reverse transcriptase in the mechanism of AZT resistance , 2000, The EMBO journal.

[16]  J. Martinez-Picado,et al.  Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. , 2000, Virology.

[17]  E. De Clercq,et al.  Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues , 2000, Antimicrobial Agents and Chemotherapy.

[18]  Christos J. Petropoulos,et al.  A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.

[19]  K. Hertogs,et al.  A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184V , 2000, Antimicrobial Agents and Chemotherapy.

[20]  E. Domingo,et al.  Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy. , 2000, Virus research.

[21]  N. Graham,et al.  The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy. , 1999, Journal of human virology.

[22]  D. Stuart,et al.  A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance , 1999, Antimicrobial Agents and Chemotherapy.

[23]  J. Martinez-Picado,et al.  Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.

[24]  W. Sugiura,et al.  Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors. , 1999, Journal of human virology.

[25]  M. Hillebrand,et al.  Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. , 1999, AIDS.

[26]  V. Soriano,et al.  Different Outcome in the First Two Patients with an HIV-1 Multinucleoside Drug-Resistant T69SSS Insertion in Spain , 1998, Antiviral therapy.

[27]  Bryan Chan,et al.  Human immunodeficiency virus reverse transcriptase and protease sequence database , 2003, Nucleic Acids Res..

[28]  E. Domingo,et al.  An RNA virus can adapt to the multiplicity of infection. , 1998, The Journal of general virology.

[29]  D. Katzenstein,et al.  A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. , 1998, The Journal of clinical investigation.

[30]  J. Fantini,et al.  Stable rearrangements of the β3–β4 hairpin loop of HIV‐1 reverse transcriptase in plasma viruses from patients receiving combination therapy , 1998, AIDS.

[31]  F. Brun-Vézinet,et al.  Switch to Unusual Amino Acids at Codon 215 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene in Seroconvertors Infected with Zidovudine-Resistant Variants , 1998, Journal of Virology.

[32]  J. Lisziewicz,et al.  Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. , 1997, The Journal of infectious diseases.

[33]  B. Larder,et al.  Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates , 1994, Antimicrobial Agents and Chemotherapy.

[34]  C. Stevens,et al.  Aquaporin 4 and glymphatic flow have central roles in brain fluid homeostasis , 2021, Nature Reviews Neuroscience.

[35]  J Desmyter,et al.  Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. , 1988, Journal of virological methods.

[36]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .